Vanguard Group Inc Bellerophon Therapeutics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.67 - $1.2 $133,587 - $239,260	-199,384 Reduced 57.76%	145,810 $131,000
Q3 2022 Nov 14, 2022	SELL	$0.96 - $1.69 $14,972 - $26,357	-15,596 Reduced 4.32%	345,194 $376,000
Q1 2022 May 13, 2022	SELL	$1.82 - $3.24 $17,768 - $31,632	-9,763 Reduced 2.63%	360,790 $852,000
Q4 2021 Feb 14, 2022	BUY	$2.36 - $4.05 $68,671 - $117,846	29,098 Added 8.52%	370,553 $1.15 Million
Q3 2021 Nov 12, 2021	BUY	$3.75 - $4.86 $16,833 - $21,816	4,489 Added 1.33%	341,455 $1.39 Million
Q2 2021 Aug 13, 2021	BUY	$3.83 - $5.65 $1.29 Million - $1.9 Million	336,966 New	336,966 $1.63 Million

44K

Ticker BLPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,545,450
Market Cap $95.5K
Description
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.